The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
Journal
Yonsei Medical Journal
Journal Volume
51
Journal Issue
1
Pages
1��8��
Date Issued
2010
Author(s)
Abstract
The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting. ? Copyright Yonsei University College of Medicine 2010.
Subjects
Bevacizumab; Cetuximab; Chemotherapy; Monoclonal antibody; Non-small cell lung cancer
SDGs
Other Subjects
anticoagulant agent; antihypertensive agent; bevacizumab; biological marker; carboplatin; cetuximab; cisplatin; docetaxel; epidermal growth factor; gemcitabine; intercellular adhesion molecule 1; monoclonal antibody; navelbine; paclitaxel; placebo; platinum derivative; vasculotropin; acne; advanced cancer; angiogenesis; Asian; bleeding; central nervous system bleeding; chemotherapy; clinical trial; diarrhea; digestive system perforation; disease course; dose response; drug efficacy; drug fatality; drug megadose; drug receptor binding; drug safety; drug targeting; epistaxis; febrile neutropenia; gastrointestinal hemorrhage; headache; high risk patient; human; hypertension; hyponatremia; injection site reaction; internalization; liver metastasis; low drug dose; lung embolism; lung hemorrhage; lung non small cell cancer; monotherapy; multiple cycle treatment; neutropenia; occlusive cerebrovascular disease; overall survival; prognosis; progression free survival; protein degradation; protein expression; proteinuria; rash; review; sepsis; signal transduction; thrombocytopenia; treatment response; Antibodies, Monoclonal; Antineoplastic Agents; Asian Continental Ancestry Group; Carcinoma, Non-Small-Cell Lung; Humans
Type
review